Sex differences in adverse events in Medicare individuals ≥ 66 years of age post glioblastoma treatment

Purpose Glioblastoma (GB) is the most common primary malignant brain tumor with the highest incidence occurring in older adults with a median age at diagnosis of 64 years old. While treatment often improves survival it brings toxicities and adverse events (AE). Here we identify sex differences in tr...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuro-oncology 2024-05, Vol.168 (1), p.111-123
Main Authors: Dmukauskas, Mantas, Cioffi, Gino, Waite, Kristin A., Sloan, Andrew E., Neff, Corey, Price, Mackenzie, Ostrom, Quinn T., Barnholtz-Sloan, Jill S.
Format: Article
Language:English
Subjects:
Adverse events
Aged
Aged, 80 and over
Brain cancer
Brain Neoplasms - epidemiology
Brain Neoplasms - therapy
Brain tumors
Chemotherapy
Combined Modality Therapy - adverse effects
Comorbidity
Diagnosis
Female
Females
Gastrointestinal diseases
Gender differences
Glioblastoma
Glioblastoma - epidemiology
Glioblastoma - therapy
Glioma
Humans
Lymphatic system
Male
Males
Medicare
Medicine
Medicine & Public Health
Neurology
Oncology
SEER Program
Sex Characteristics
Sex differences
Sex Factors
United States - epidemiology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Glioblastoma (GB) is the most common primary malignant brain tumor with the highest incidence occurring in older adults with a median age at diagnosis of 64 years old. While treatment often improves survival it brings toxicities and adverse events (AE). Here we identify sex differences in treatment patterns and AE in individuals ≥ 66 years at diagnosis with GB. Methods Using the SEER-Medicare dataset sex differences in adverse events were assessed using multivariable logistic regression performed to calculate the male/female odds ratio (M/F OR) and 95% confidence intervals [95% CI] of experiencing an AE adjusted for demographic variables and Elixhauser comorbidity score. Results Males with GB were more likely to receive standard of care (SOC; Surgery with concurrent radio-chemotherapy) [20%] compared to females [17%], whereas females were more likely to receive no treatment [26%] compared to males [21%]. Females with GB receiving SOC were more likely to develop gastrointestinal disorders (M/F OR = 0.76; 95% CI,0.64–0.91, p  = 0.002) or blood and lymphatic system disorders (M/F OR = 0.79; 95% CI,0.66–0.95, p  = 0.012). Males with GB receiving SOC were more likely to develop cardiac disorders (M/F OR = 1.21; 95% CI,1.02–1.44, p  = 0.029) and renal disorders (M/F OR = 1.65; 95% CI,1.37–2.01, p  
ISSN:0167-594X
1573-7373
1573-7373
DOI:10.1007/s11060-024-04652-z